Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2023; 11(6): 1275-1286
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1275
Implications of metabolic dysfunction associated fatty liver disease in COVID-19
Raja Chakraborty, Deepak Sharma, Devesh U Kapoor, Akanksha Dwivedi, Rakhi Khabiya, Saikat Sen
Raja Chakraborty, Institute of Pharmacy, Assam Don Bosco University, Guwahati 782402, Assam, India
Deepak Sharma, School of Medical Sciences, Adamas University, Kolkata 700126, West Bengal, India
Devesh U Kapoor, Department of Pharmacy, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India
Akanksha Dwivedi, Rakhi Khabiya, Department of Pharmacy, Acropolis Institute of Pharmaceutical Education & Research, Indore 453771, Madhya Pradesh, India
Saikat Sen, Faculty of Pharmaceutical Science, Assam down town University, Guwahati 781026, Assam, India
Author contributions: Chakraborty R and Sen S designed the structure of the paper; Sharma D, Kapoor DU, Khabiya R, and Dwivedi A collected the data; all the authors contributed to the writing of the paper; Chakraborty R and Sen S performed compilation and reviewed the paper.
Conflict-of-interest statement: All the author declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Saikat Sen, PhD, Professor, Faculty of Pharmaceutical Science, Assam Down Town University, Gandhinagar, Panikhaiti, Guwahati 781026, Assam, India. saikat.pharm@rediffmail.com
Received: November 2, 2022
Peer-review started: November 2, 2022
First decision: November 24, 2022
Revised: December 20, 2022
Accepted: January 31, 2023
Article in press: January 31, 2023
Published online: February 26, 2023
Abstract

Metabolic associated fatty liver disorder (MAFLD) characterizes the contributing etiologies (i.e., type 2 diabetes mellitus, metabolic syndrome, overweight) of individuals with fatty liver disease that affects 1/3rd of the world population. In 2020, the coronavirus disease 2019 (COVID-19) crisis was unprecedented, and people with different comorbidities became more susceptible to the infection caused by severe acute respiratory syndrome coronavirus 2. MAFLD patients are frequently obese with added metabolic menace like diabetes, hypertension, and dyslipidemia leading to greater jeopardy of COVID-19. MAFLD patients are 4 to 6-fold more prone towards infections. COVID-19 induces liver injury with elevated levels of aspartate aminotransferase and alanine aminotransferase and insignificantly elevated bilirubin. Hence, MAFLD in COVID-19 patients worsens the condition significantly. The evidence highlighting the interaction between MAFLD and altered liver functioning in COVID-19 suggested that COVID-19 patients with pre-existing MAFLD are at greater risk of morbidity or intensive care unit admission. Direct hepatic injury, enhanced levels of inflammatory cytokines, declined hepatic mitochondrial activity, and compromised immunity are considered as some underlying mechanisms. The main focus of this review is to discuss the implications of metabolic dysfunction associated with fatty liver disease in COVID-19 patients. The review systematically analyzes the effect of striking two worldwide pandemics (MAFLD and COVID-19) together in the present era.

Keywords: Metabolic associated fatty liver disorder, COVID-19, Metabolic dysfunction, Hepatic damage, Cytokine storm

Core Tip: Metabolic associated fatty liver disorder (MAFLD) is associated with fat accumulation and inflammation in hepatocytes, thus compromising liver function and making people more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, cytokine storm in SARS-CoV-2 infected MAFLD patients is considered severe and requires urgent attention. In addition, direct hepatic injury caused by SARS-CoV-2, enhanced levels of inflammatory cytokines, declined hepatic mitochondrial activity, compromised immunity, and altered expression of host angiotensin-converting enzyme 2 receptor are considered as some underlying mechanisms. Thus, patients with MAFLD require special attention to protect themselves from the SARS-CoV-2 infection or severe illness caused by SARS-CoV-2.